Table 2.
Weight change in each group.
| Group | Morbidity (%) | Survival rate (%) | Weight before infection (g) | Weight post infection (g) | Body weight gain (g) | Relative weight gain (%) |
|---|---|---|---|---|---|---|
| Experimental 1 | ||||||
| Oral 50 k | 0 | 100 | 183.3 ± 6.1a | 473.3 ± 12.3a | 290.0 ± 14.1a | 96.7 |
| Oral 100 k | 0 | 100 | 183.3 ± 6.9a | 471.2 ± 13.0a | 287.9 ± 14.0a | 96 |
| Oral 200 k | 30 | 100 | 183.3 ± 5.9a | 452.7 ± 17.6b | 269.4 ± 14.2b | 89.9 |
| Intracloacal 50 k | 0 | 100 | 183.2 ± 7.0a | 471.6 ± 14.6a | 288.4 ± 13.3a | 96.2 |
| Intracloacal 100 k | 50* | 100 | 183.2 ± 5.9a | 451.4 ± 23.0b | 268.2 ± 21.2b | 89.5 |
| Intracloacal 200 k | 60* | 90 | 183.2 ± 6.4a | 415.8 ± 18.6c | 232.6 ± 20.6c | 77.6 |
| NC | 0 | 100 | 183.4 ± 5.7a | 483.1 ± 15.8a | 299.6 ± 13.1a | 100 |
| Experimental 2 | ||||||
| D10 | 80* | 100 | 183.1 ± 6.1a | 421.1 ± 26.7b | 237.8 ± 25.7b | 74.9 |
| D168 | 20 | 100 | 183.1 ± 5.5a | 482.1 ± 21.2a | 298.9 ± 20.1a | 94.2 |
| NC | 0 | 100 | 183.2 ± 4.8a | 500.3 ± 18.4a | 317.1 ± 19.3a | 100 |
| Experimental 3 | ||||||
| Vacc Intracloacal 50 k | 70* | 100 | 181.4 ± 5.8a | 764.4 ± 19.5b | 582.8 ± 18.7b | 92.7 |
| Vacc Intracloacal 100 k | 20 | 100 | 181.5 ± 4.7a | 769.1 ± 16.2b | 587.4 ± 16.5b | 93.4 |
| Vacc Intracloacal 200 k | 20 | 100 | 181.7 ± 5.8a | 785.3 ± 47.6ab | 603.6 ± 44.3ab | 96.0 |
| PC | 80* | 100 | 181.6 ± 4.9a | 686.2 ± 36.3c | 504.7 ± 34.4c | 80.3 |
| NC | 0 | 100 | 181.8 ± 4.0a | 810.1 ± 30.4a | 628.3 ± 28.5a | 100 |
| Experimental 4 | ||||||
| d3 Vacc | 40 | 100 | 40.4 ± 0.8a | 744.9 ± 28.6b | 704.5 ± 28.4b | 94.8 |
| d14 Vacc | 30 | 100 | 40.4 ± 1.0a | 755.0 ± 25.1ab | 714.6 ± 24.6ab | 96.2 |
| d3/14 Vacc | 40 | 100 | 40.0 ± 0.8a | 755.9 ± 24.8ab | 715.9 ± 24.5ab | 96.3 |
| PC | 70* | 100 | 40.4 ± 0.9a | 637.1 ± 45.8c | 596.6 ± 45.7c | 80.3 |
| NC | 0 | 100 | 40.6 ± 1.0a | 783.5 ± 27.3a | 742.8 ± 28.0a | 100 |
*Indicates significant difference in morbidities (P < 0.05) as compared to the NC group with chi-square test. Values of body weight data within a column with no common superscript differ significantly (p < 0.05). Experiment 1 group: Oral 50 k, oral infection at a dose of 5 × 104 JSYZ-D10 H. meleagridis/chicken; Oral 100 k, oral infection at a dose of 1 × 105 JSYZ-D10 H. meleagridis/chicken; Oral 200 k, oral infection at a dose of 2 × 105 JSYZ-D10 H. meleagridis /chicken; Intracloacal 50 k, intracloacal infection at a dose of 5 × 104 JSYZ-D10 H. meleagridis /chicken; Intracloacal 100 k, intracloacal infection at a dose of 1 × 105 JSYZ-D10 H. meleagridis /chicken; Intracloacal 200 k, intracloacal infection at a dose of 2 × 105 JSYZ-D10 H. meleagridis /chicken; NC, non-challenged control. Experiment 2 group: D10, intracloacal infection at a dose of 2 × 105 JSYZ-D10 H. meleagridis/chicken; D168, intracloacal infection at a dose of 2 × 105 JSYZ-D168 H. meleagridis/chicken; NC, non-challenged control. Experiment 3 group: Vacc Intracloacal 50 k, intracloacal immunization at a dose of 5 × 104 JSYZ-D168 H. meleagridis/chicken; Vacc Intracloacal 100 k, intracloacal immunization at a dose of 1 × 105 JSYZ-D168 H. meleagridis/chicken; Vacc Intracloacal 200 k, intracloacal immunization at a dose of 2 × 105 JSYZ-D168 H. meleagridis/chicken; PC, positive-challenged control; NC, non-challenged control. Experiment 4 group: d3 Vacc, intracloacal immunization at a dose of 2 × 105 JSYZ-D168 H. meleagridis/chicken at 3 days of age; d14 Vacc, intracloacal immunization at a dose of 2 × 105 JSYZ-D168 H. meleagridis/chicken at 14 days of age; d3/14 Vacc, intracloacal immunization at a dose of 2 × 105 JSYZ-D168 H. meleagridis/chicken at 3 and 14 days of age, respectively; PC, positive-challenged control; NC, non-challenged control.